tiprankstipranks
Kyverna Therapeutics price target lowered to $6 from $7 at H.C. Wainwright
PremiumThe FlyKyverna Therapeutics price target lowered to $6 from $7 at H.C. Wainwright
1M ago
Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo
Premium
The Fly
Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo
1M ago
Premium
Company Announcements
Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs
1M ago
Kyverna Therapeutics initiated with a Buy at UBS
PremiumThe FlyKyverna Therapeutics initiated with a Buy at UBS
2M ago
Kyverna Therapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Kyverna Therapeutics initiated with a Buy at Rodman & Renshaw
2M ago
Kyverna treatment of systemic sclerosis granted FDA orphan designation
Premium
The Fly
Kyverna treatment of systemic sclerosis granted FDA orphan designation
3M ago
Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
PremiumThe FlyKyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
4M ago
Kyverna Therapeutics reports Q2 EPS (67c), consensus (70c)
Premium
The Fly
Kyverna Therapeutics reports Q2 EPS (67c), consensus (70c)
4M ago
Kyverna Therapeutics receives U.S. FDA RMAT designation for KYV-101
Premium
The Fly
Kyverna Therapeutics receives U.S. FDA RMAT designation for KYV-101
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100